Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.06 USD
Change Today -0.37 / -4.98%
Volume 1.6M
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 5:20 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$7.33
Previous Close
$7.43
Day High
$7.42
Day Low
$7.05
52 Week High
03/5/15 - $8.59
52 Week Low
10/13/14 - $2.98
Market Cap
1.0B
Average Volume 10 Days
1.6M
EPS TTM
$-0.47
Shares Outstanding
141.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

198 Employees
Last Reported Date: 08/15/14
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Chief Operating Officer
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

Array BioPharma Inc. Announces Preliminary Data from Phase Ib/II Melanoma Study

Array BioPharma Inc. has announced preliminary data from a Phase Ib/II dose escalation and expansion study with the combination of binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity consistent with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range currently being used in the Phase III COLUMBUS trial. Array expects updated BRAF melanoma data from the ongoing Phase II combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be submitted to a scientific conference later 2015. LOGIC-2 utilizes the same dose of binimetinib and encorafenib currently being studied in the COLUMBUS trial. In the study, patients were treated with binimetinib 45 mg twice daily (BID) and increasing doses of encorafenib once daily (QD) (over the range of 50 to 800 mg and including doses of 400 and 450 mg, which are comparable to the 450 mg dose being used in the Phase III COLUMBUS trial), followed by an expansion phase at the maximum tolerated dose of 600 mg QD. The objective response rate (confirmed complete response or partial response) reported in the trial was 75% (41 of 55) for BRAF-naive patients, including 78% (7 of 9) of patients treated with the encorafenib 400/450 mg dose. The estimated median overall progression-free survival for BRAF-naive patients was 11.3 months. These results are consistent with MEK/RAF inhibitor expectations in BRAF-mutant melanoma patients. Preliminary data from the study also indicate that in combination with binimetinib, encorafenib was tolerated at doses up to 600 mg, twice its single-agent maximum tolerated dose. At the 400/450 mg dose of encorafenib, with few grade 3 /4 events and an 11% incidence of pyrexia and photosensitivity, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging.

Array BioPharma Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM

Array BioPharma Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

Array BioPharma, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 12:00 PM

Array BioPharma, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 12:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $7.06 USD -0.37

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.30 USD -0.09
CTI BioPharma Corp $1.93 USD -0.14
Evotec AG €3.51 EUR -0.078
Exelixis Inc $3.54 USD -0.23
Progenics Pharmaceuticals Inc $6.56 USD -0.25
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.8x
Price/Book 20.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.